YLYuxian Lei

Yuxian Lei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yuxian Lei has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Gavin A. Bewick

    Department of Diabetes, School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, Guy's Campus, London SE1 1UL, UK. Diabetes, Endocrinology and Obesity clinical academic partnership, Kings Health Partners, London

    4 shared publications
  • Naila Haq

    Department of Diabetes, School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, Guy's Campus, London SE1 1UL, UK. 2.Diabetes, Endocrinology and Obesity clinical academic partnership, Kings Health Partners, London, UK.

    3 shared publications
  • Bettina Bohl

    Imperial College London

    2 shared publications
  • Kevin Graeme Murphy

    Section of Endocrinology and Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, UK

    2 shared publications
  • Leah Meyer

    Imperial College London

    2 shared publications
  • Margot Jacobs

    King's College London

    2 shared publications

Latest Publications

  • Open Access

    Neuropeptide Y4 receptor activation delays autoimmune diabetes by reprogramming β-cell stress and immune tolerance

    by Naila A Haq, Klaudia W Toczyska, Anowara Islam, Oladapo Edward Olaniru, Yuxian Lei, Ming Hu, Min Zhao, Ronny Müller, Mohammed Kamran Afzal Mirza, Nick Fine, et al.

    Type 1 diabetes (T1D) involves immune-mediated destruction of pancreatic β-cells, yet current disease-modifying therapies mainly target immunity without enhancing β-cell resilience. We show selective neuropeptide Y4 receptor (Y4R) agonism protects β-cells while reshaping islet immunity across T1D models. Multi-modal localisation using cell sorting, qPCR, RNAscope and fluorescent ligand competition demonstrated predominant Y4R expression and functional accessibility on mouse and human β-cells. Selective Y4R agonism was non-toxic and did not impair islet network integrity, Ca+ dynamics, glucose-stimulated insulin secretion or systemic glucose tolerance. Y4R activation conferred cytoprotection against inflammatory cytokines, streptozotocin, lipotoxicity and ER stress, reducing caspase-3/7 activation and β-cell loss whilst sustaining insulin release and promoting proliferation in both mouse and human islets. Bulk RNA-seq revealed a coordinated β-cell resilience programme characterised by reinforced identity and insulin processing, KEAP1-NFE2L2-driven antioxidative and proteostatic activation, and suppression of EIF2 signalling and associated biosynthetic and ER stress pathways. Concurrently, Y4R agonism dampened pathogenic chemokine and cytokine networks, including CXCL10, CCL3/4/7 and IL-6, while preserving IL-2 and Foxp3 signals, thereby limiting CD8+ T cell, CD4+T cell and macrophage chemotaxis toward cytokine-stressed islets. Reduced immune-cell recruitment was conserved in a fully human immune-islet system, where Y4R activation significantly attenuated IL-2-activated human PBMC migration and invasion toward cytokine-stressed human islets. In a stringent NY8.3 CD8+ T cell adoptive-transfer model, systemic Y4R agonism significantly delayed diabetes onset. These data position Y4R as a β-cell-centric therapeutic target coupling intrinsic resilience with local immune modulation, offering a complementary approach for β-cell preservation in T1D and islet replacement therapies.

  • Open Access

    Mapping the druggable targets displayed by human colonic enteroendocrine cells

    by Gavin Bewick, Yuxian Lei, Bettina Bohl, Leah Meyer, Margot Jacobs, Naila Haq, Xiaoping Yang, Bu’ Hussain Hayee, Kevin Murphy, Parastoo Hashemi

    Enteroendocrine cells (EECs) are specialized intestinal hormone-secreting cells that play critical roles in metabolic homeostasis, digestion, and gut-brain communication. They detect diverse stimuli including endocrine, immune, neuronal, microbial, and dietary signals, through a complex array of receptors, ion channels, and transporters, to modulate the release of over 20 hormones. These molecular sensors serve as potential drug targets to modulate hormone secretion, but until recently, catalogues of such targets in human colonic EECs have not been produced. To address this gap, we performed bulk and single-cell RNA sequencing on fluorescently labelled EECs isolated from human colonic organoids, identifying and cataloguing potential druggable targets. This catalogue includes receptors, orphan GPCRs, transporters, and hormones not previously reported in human colonic EECs. Comparison with murine EECs highlighted interspecies similarities and differences, key data to facilitate the design and optimise the predictive accuracy of pre-clinical models. We also functionally validated two receptors not previously identified in human EECs: IL-13Rα1, was expressed in both peptide-producing EECs and serotonin producing Enterochromaffin cells (ECs), and its ligand IL-13 stimulated the secretion of glucagon-like peptide-1 (GLP-1) and serotonin measured in real-time, and GPR173, which was selectively expressed in ECs and, when activated by its agonist Phoenixin-20, also promoted serotonin release. These analyses provide a valuable resource for therapeutic interventions aimed at modulating gut hormone secretion, with potential applications in treating gastrointestinal, metabolic, and other related disorders.

  • Open Access

    Mapping the druggable targets displayed by human colonic enteroendocrine cells

    by Yuxian Lei, Bettina Bohl, Leah Meyer, Margot Jacobs, Naila Haq, Xiaoping Yang, Bu’ Hussain Hayee, Kevin G Murphy, Parastoo Hashemi, Gavin A Bewick

    Enteroendocrine cells (EECs) are specialized intestinal hormone-secreting cells that play critical roles in metabolic homeostasis, digestion, and gut-brain communication. They detect diverse stimuli including endocrine, immune, neuronal, microbial, and dietary signals, through a complex array of receptors, ion channels, and transporters, to modulate the release of over 20 hormones. These molecular sensors serve as potential drug targets to modulate hormone secretion, but until recently, catalogues of such targets in human colonic EECs have not been produced. To address this gap, we performed bulk and single-cell RNA sequencing on fluorescently labelled EECs isolated from human colonic organoids, identifying and cataloguing potential druggable targets. This catalogue includes receptors, orphan GPCRs, transporters, and hormones not previously reported in human colonic EECs. Comparison with murine EECs highlighted interspecies similarities and differences, key data to facilitate the design and optimise the predictive accuracy of pre-clinical models. We also functionally validated two receptors not previously identified in human EECs: IL-13Rα1, was expressed in both peptide-producing EECs and serotonin producing Enterochromaffin cells (ECs), and its ligand IL-13 stimulated the secretion of glucagon-like peptide-1 (GLP-1) and serotonin measured in real-time, and GPR173, which was selectively expressed in ECs and, when activated by its agonist Phoenixin-20, also promoted serotonin release. These analyses provide a valuable resource for therapeutic interventions aimed at modulating gut hormone secretion, with potential applications in treating gastrointestinal, metabolic, and other related disorders.


  • Open Access

    Aryl hydrocarbon receptor utilises cellular zinc signals to maintain the gut epithelial barrier

    by Xiuchuan (Lucas) Hu, Wenfeng Xiao, Yuxian Lei, Adam Green, Xinyi Lee, Muralidhara Rao Maradana, Yajing Gao, Xueru Xie, Rui Wang, George Chennell, et al.

    Zinc and plant-derived ligands of the aryl hydrocarbon receptor (AHR) are dietary components affecting intestinal epithelial barrier function. Here, we explore whether zinc and the AHR pathway are linked. We show that dietary supplementation with an AHR pre-ligand offers protection against inflammatory bowel disease in a mouse model while protection fails in mice lacking AHR in the intestinal epithelium. AHR agonist treatment is also ineffective in mice fed zinc depleted diet. In human ileum organoids and Caco-2 cells, AHR activation increases total cellular zinc and cytosolic free Zn2+ concentrations through transcription of genes for zinc importers. Tight junction proteins are upregulated through zinc inhibition of nuclear factor kappa-light-chain-enhancer and calpain activity. Our data show that AHR activation by plant-derived dietary ligands improves gut barrier function at least partly via zinc-dependent cellular pathways, suggesting that combined dietary supplementation with AHR ligands and zinc might be effective in preventing inflammatory gut disorders.